We are live on ! Find out more
PAI

ProQuest Associates IV Portfolio holdings

AUM $53M
1-Year Est. Return 3.35%
This Fund
S&P 500
This Quarter Est. Return
+66.94%
1 Year Est. Return
+3.35%
3 Year Est. Return
+113.14%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$117M
Cap. Flow
-$22M
Cap. Flow %
-6.07%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$22M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EGRX
1
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$307M 84.52%
4,382,764
-397,424
-8% -$22M
AGRX
2
DELISTED
Agile Therapeutics
AGRX
$35.3M 9.73%
2,531
– –
IMDZ
3
DELISTED
Immune Design Corp.
IMDZ
$14.9M 4.1%
1,962,720
– –
ANTH
4
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.99M 1.65%
237,500
– –

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
HC
Hampstead Capital London, United Kingdom $55.8M AUM 2.76% 1-Year Est. Return
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
MCAI
Meritech Capital Associates III Palo Alto, California $45.8M AUM 24.9% 1-Year Est. Return
P
PhaseCapital New York $45.2M AUM 8.85% 1-Year Est. Return

ProQuest Associates IV's Q3 2016 Portfolio in Review

As of Q3 2016, ProQuest Associates IV held 4 positions worth $363M, up 48% from $246M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ProQuest Associates IV withdrew a net $22M in Q3 2016, reducing 1 holding. Its largest reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $22M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ProQuest Associates IV's biggest Q3 2016 reduction was Eagle Pharmaceuticals, Inc., cutting an estimated $22M.
  • ProQuest Associates IV's ten largest holdings make up 100% of its $363M portfolio in Q3 2016.
  • ProQuest Associates IV opened 0 new positions and closed 0 in Q3 2016.
  • ProQuest Associates IV's portfolio value rose 48% quarter-over-quarter to $363M.

Based on ProQuest Associates IV's 13F filing for Q3 2016, filed 14 Nov 2016.